Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer
Neoadjuvant Therapy With FEC Followed by Weekly Paclitaxel and Concurrent Trastuzumab in Her2 Positive Non Operable Breast Cancer. Phase II Study.
Sponsor: Lucia Del Mastro,MD
This PHASE2 trial investigates HER-2 Positive Breast Cancer and is currently completed. Lucia Del Mastro,MD leads this study, which shows 10 recorded versions since 2011 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2022 — Jun 2024 [monthly]
Active Not Recruiting PHASE2
-
May 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE2
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Nov 2018 — May 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Mar 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Lucia Del Mastro,MD
For direct contact, visit the study record on ClinicalTrials.gov .